PRISM-GENOMICS-Smoking Cessation for Patients With Coronary Artery Disease Undergoing Cardiac Catheterization or Having a Heart Attack at Barnes Hospital in St. Louis Mo
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease, Smoking Cessation, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/6/2018 |
| Start Date: | July 21, 2015 |
| End Date: | July 21, 2025 |
| Contact: | Sharon Cresci |
| Email: | scresci@wustl.edu |
| Phone: | 3143625363 |
Angina and Genotype-Guided Smoking Cessation In PRISM-GENOMICS
It has previously been shown that patients with coronary artery disease may have a harder
time quitting smoking if they have a specific genetic profile and that these individuals have
a better chance at quitting if they receive nicotine replacement therapy. The investigators
hypothesize that determining which individuals with coronary artery disease should receive
nicotine replacement therapy based on their genotype may improve the number of individuals
who are able to quit smoking.This study randomizes treatment to that determined by the
patient's genotype compared to standard, non-genotype-guided, treatment.
time quitting smoking if they have a specific genetic profile and that these individuals have
a better chance at quitting if they receive nicotine replacement therapy. The investigators
hypothesize that determining which individuals with coronary artery disease should receive
nicotine replacement therapy based on their genotype may improve the number of individuals
who are able to quit smoking.This study randomizes treatment to that determined by the
patient's genotype compared to standard, non-genotype-guided, treatment.
In this study, the investigators propose to show the feasibility of incorporating
genotype-guided therapy into post-MI smoking cessation therapy and/or smoking cessation
therapy in patients with coronary artery disease (CAD) using the CHRNA5 rs16969968 variant as
the pilot case. The investigators propose to genotype ½ of PRISM-GENOMICs patients who are
active smokers within 48 hours of admission and to guide their smoking cessation therapy
based on CHRNA5 rs16969968 genotype (A allele carriers will be given pharmacologic therapy
and GG homozygotes will be given counseling). The investigators will use the other ½ as
controls. The participants will be followed and the investigators will test whether the
genotype-guided group has better rates of smoking cessation compared to the control group.
This pilot study will lay the foundation for personalized, genotype-guided, post-MI therapy
and/or therapy in patients with CAD.
genotype-guided therapy into post-MI smoking cessation therapy and/or smoking cessation
therapy in patients with coronary artery disease (CAD) using the CHRNA5 rs16969968 variant as
the pilot case. The investigators propose to genotype ½ of PRISM-GENOMICs patients who are
active smokers within 48 hours of admission and to guide their smoking cessation therapy
based on CHRNA5 rs16969968 genotype (A allele carriers will be given pharmacologic therapy
and GG homozygotes will be given counseling). The investigators will use the other ½ as
controls. The participants will be followed and the investigators will test whether the
genotype-guided group has better rates of smoking cessation compared to the control group.
This pilot study will lay the foundation for personalized, genotype-guided, post-MI therapy
and/or therapy in patients with CAD.
Inclusion Criteria:
- Adult
- presenting to Barnes hospital cardiac catheterization laboratory with coronary artery
disease or admitted to Barnes hospital within 24 hours of a type 1 myocardial
infarction (heart attack)
- active smoker at time of presentation to Barnes Hospital
- participating in PRISM-GENOMICS observational study
Exclusion Criteria:
- Unable to provide informed consent
- Unable to answer questions (e.g. intubated)
- Incarcerated
- Complications of myocardial infarction (such as shock, hemodynamic instability, life-
threatening infection, etc)
- Women of child-bearing age with positive pregnancy test or who is breast feeding
We found this trial at
1
site
4483 Duncan Avenue
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
Principal Investigator: Sharon Cresci, MD
Click here to add this to my saved trials
